Biora Therapeutics, Inc. (BIOR)

NASDAQ: BIOR · IEX Real-Time Price · USD
0.730
-0.008 (-1.03%)
At close: May 17, 2024, 4:00 PM
0.749
+0.019 (2.63%)
After-hours: May 17, 2024, 7:53 PM EDT
-1.03%
Market Cap 26.44M
Revenue (ttm) 544,000
Net Income (ttm) -110.86M
Shares Out 35.88M
EPS (ttm) -5.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 205,405
Open 0.740
Previous Close 0.737
Day's Range 0.700 - 0.750
52-Week Range 0.585 - 6.700
Beta 1.23
Analysts Strong Buy
Price Target 15.00 (+1,955.64%)
Earnings Date May 15, 2024

About BIOR

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 19, 2020
Employees 58
Stock Exchange NASDAQ
Ticker Symbol BIOR
Full Company Profile

Financial Performance

In 2023, BIOR's revenue was $4,000, a decrease of -98.69% compared to the previous year's $305,000. Losses were -$124.12 million, 225.3% more than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for BIOR stock is "Strong Buy" and the 12-month stock price forecast is $15.0.

Price Target
$15.0
(1,955.64% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented a...

3 days ago - GlobeNewsWire

Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and ...

11 days ago - GlobeNewsWire

Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical data on...

12 days ago - GlobeNewsWire

Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600

Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024 SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (N...

18 days ago - GlobeNewsWire

Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology

SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent relate...

5 weeks ago - GlobeNewsWire

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development

All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no saf...

6 weeks ago - GlobeNewsWire

Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously annou...

6 weeks ago - GlobeNewsWire

Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definitive...

6 weeks ago - GlobeNewsWire

Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial. Management to host conference call today at 4:30 PM ET.

7 weeks ago - GlobeNewsWire

Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results an...

2 months ago - GlobeNewsWire

Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset

Monetization of legacy asset brings in $3 million in nondilutive capital Convertible notes exchange brings in another $2.8 million in new capital and reduces Biora's net debt SAN DIEGO, March 11, 2024...

2 months ago - GlobeNewsWire

Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600

Data expected to be shared during March corporate update With SAD cohorts complete, MAD cohorts to begin dosing in March SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq:...

2 months ago - GlobeNewsWire

Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium

SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will participate in the Inflamma...

3 months ago - GlobeNewsWire

Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.

SAN DIEGO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced participation in a virtual fireside ...

4 months ago - GlobeNewsWire

Biora Therapeutics Provides Outlook for 2024

Biora anticipates 2024 catalysts, including clinical study results for NaviCap™ platform and progress on pharma partnerships for BioJet™ platform.

4 months ago - GlobeNewsWire

Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600

First-in-human trial of BT-600 drug-device combination, following multiple successful device-only human studies SAD/MAD study to evaluate safety and PK/PD of BT-600, including concentrations in colon ...

4 months ago - GlobeNewsWire

Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform

SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that its BioJet™ Systemic Oral Deliv...

4 months ago - GlobeNewsWire

Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform

SAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it received an Issue Notificati...

5 months ago - GlobeNewsWire

Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors

Transaction results in nearly 60% reduction in net debt and brings $16 million in new capital; demonstrates investor confidence in near-term catalysts.

5 months ago - GlobeNewsWire

Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform

SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced a new research collaboration with a ...

5 months ago - GlobeNewsWire

Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis

BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nas...

6 months ago - GlobeNewsWire

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

NaviCap™ Targeted Oral Delivery platform advancing toward initiation of phase 1 clinical trial by year end Pharma collaborations accelerate for the BioJet™ Systemic Oral Delivery platform, which shows...

6 months ago - GlobeNewsWire

Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Biora will report financial results and provide a corporate update for the third quarter on on Monday, November 13, 2023, at 4:30 PM EST / 1:30 PM PST

6 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biora Therapeutics, Inc. - BIOR

NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biora Therapeutics, Inc. ("Biora" or the "Company") (NASDAQ: BIOR). Such investors are advised t...

7 months ago - PRNewsWire

Biora Therapeutics Submits Updated IND Application for BT-600

Update includes supplemental information and provides additional time to complete regulatory review; company expects to remain on track with Ph1 timeline.

7 months ago - GlobeNewsWire